Febrile neutrophilic dermatosis [Sweet]

L12_FEBRILENEUTROPHIL

skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519972
1. Apply sex-specific rule None	519972
2. Check conditions None	519972
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — L98.2 Cause of death: ICD-10 — L98.2 2 out of 7 registries used, show all original rules.	52
4. Check minimum number of events None	52
5. Include endpoints None	52
6. Filter based on genotype QC (FinnGen only)	51

Control definitions (FinnGen only)

Control exclude: L12_OTHERSKINSUBCUTIS

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: L98
Name in latin: Dermatosis neutrophila febrilis (Sweet)

NAME	L12_FEBRILENEUTROPHIL
CONTROL_EXCLUDE	L12_OTHERSKINSUBCUTIS
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	L982
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	L982
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Febrile neutrophilic dermatosis [Sweet] based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Sweet's syndrome

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	272	141	130
Only index persons	252	130	122
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	58.60	57.94	59.42
Only index persons	57.46	55.77	59.27

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	51	34	17
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	61.50	61.53	61.42

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
52: Matched controls
520

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

L98.2

ICD-10 Finland

Febrile neutrophilic dermatosis [Sweet]

+∞

74.4

L30.9

ICD-10 Finland

Dermatitis, unspecified

14.4

22.0

TQX10

NOMESCO Finland

Biopsy of skin and subcutaneous tissue

20.4

16.6

R50.9

ICD-10 Finland

Fever, unspecified

9.3

14.5

A49.9

ICD-10 Finland

Bacterial infection, unspecified

11.8

10.8

H02AB06

ATC

prednisolone; systemic

6.5

8.6

176

L04AX01

ATC

azathioprine; systemic

35.5

7.4

GD1AA

NOMESCO Finland

Thorax X-ray examination

5.3

7.0

187

JN3AE

NOMESCO Finland

Abdominal ultrasound examination

6.7

6.5

117

Kela drug reimbursment

Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue

15.1

6.4

A46

ICD-10 Finland

Erysipelas

5.2

6.3

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768443) Skin Pathology biopsy report

21.05

14.03

1.6

1.1

—

(3007164) IgA [Mass/volume] in Serum or Plasma

6.36

10.24

2.2

1.3

3.08

2.60

g/l

0.27

(3037522) Nuclear Ab [Titer] in Serum

6.74

10.03

1.7

1.4

274.29

430.00

titre

—

(40763571) Iron/Transferrin [Ratio] in Serum or Plasma

6.44

9.77

2.6

2.2

24.23

21.69

0.21

(3004588) Protein electrophoresis panel - Serum or Plasma

10.13

9.60

5.6

1.3

—

(40760892) CBC W Ordered Manual Differential panel - Blood

198

7.74

9.33

20.6

5.6

—

(3021440) Promyelocytes/100 leukocytes in Blood

7.29

7.20

8.4

4.9

0.11

0.00

—

(3017181) Myelocytes/100 leukocytes in Blood

7.07

7.06

8.5

4.8

0.67

0.31

—

(3023368) Bacteria identified in Blood by Culture

119

4.25

6.23

10.6

4.4

—

(40760888) Immunoglobulin light chains.free panel - Serum

17.72

6.15

6.2

9.7

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

4.53

6.10

2.1

1.8

—

(3002179) Metamyelocytes/100 leukocytes in Blood

6.52

6.09

8.6

4.8

0.38

0.00

—

(3025159) Blasts/100 leukocytes in Blood

6.52

6.09

8.9

5.1

0.14

0.00

—

(3007853) Bacteria identified in Skin by Aerobe culture

4.89

6.08

3.1

1.4

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

4.89

6.08

3.0

4.2

—

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

15.16

5.82

5.4

1.4

60.56

56.86

—

(3037756) Immunofixation for Serum or Plasma

15.16

5.82

5.0

1.3

—

(3042936) Bacteria identified in Isolate by Culture

4.41

5.74

3.8

2.3

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

6.69

5.58

1.5

1.3

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

7.16

5.50

5.5

1.0

—

(3000093) Morphology [Interpretation] in Blood Narrative

+∞

5.29

1.4

0.0

—

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

+∞

5.29

1.8

0.0

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

11.77

5.26

2.1

1.9

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

13.19

4.97

4.1

1.1

4.76

5.46

e9/l

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

4.28

4.75

1.7

1.6

—

(3043849) Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection

15.84

4.72

1.1

1.8

—

(3000012) Reticulocyte production index

15.84

4.72

2.3

2.2

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

11.53

4.70

1.5

1.8

—

(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma

13.19

4.41

1.1

1.2

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

13.19

4.41

1.1

1.2

—

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

11.29

4.14

1.1

1.3

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

156

3.18

4.03

3.5

3.3

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

8.35

4.02

1.4

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

5.52

4.02

1.4

—

(3022217) INR in Platelet poor plasma by Coagulation assay

191

3.25

3.99

11.1

12.2

1.21

1.24

inr

0.10

(3000494) Fungus identified in Specimen by Culture

3.73

3.96

1.3

1.5

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

4.60

3.95

1.4

1.5

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

134

3.11

3.90

3.3

2.1

153.00

156.76

u/l

0.02

127

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

3.80

3.87

1.6

1.7

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

3.65

3.85

1.5

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

7.64

3.83

2.0

1.3

1.06

1.20

g/l

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

7.64

3.83

2.1

1.3

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

204

3.19

3.78

12.4

5.7

1.19

1.22

mmol/l

1.06

175

(3037467) Urinalysis macro (dipstick) panel - Urine

292

3.72

3.76

5.6

4.2

—

(3020779) Urea [Moles/volume] in Serum or Plasma

4.56

3.69

5.5

4.2

5.97

8.50

mmol/l

1.03

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

7.15

3.30

1.6

1.0

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

7.15

3.30

1.1

1.7

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

7.15

3.30

1.3

1.1

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

3.05

3.27

1.6

1.3

33.40

5.06

u/ml

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

6.55

3.13

1.1

1.3

—

(3018418) pH of Serum or Plasma

139

2.74

3.13

6.7

3.6

7.41

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

10.86

3.04

2.8

2.2

31.40

—

(3026008) Bacteria identified in Urine by Culture

133

2.69

3.01

2.4

2.7

—

(36304419) Bacteria [Presence] in Urine

134

2.67

2.96

3.3

2.8

—

(3022145) Colonoscopy Study observation

3.11

2.90

1.6

1.5

—

(3035350) Ketones [Presence] in Urine by Test strip

215

2.68

2.84

3.3

3.7

0.00

estimate

-0.00

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

9.04

2.81

1.4

1.5

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

9.04

2.81

1.4

1.5

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

9.04

2.81

1.4

1.5

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

9.04

2.81

1.4

1.5

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

9.04

2.81

1.4

1.5

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

9.04

2.81

1.4

1.5

—

(40761536) Microorganisms panel - Urine sediment

3.17

2.67

4.6

3.9

—

(3031040) Bacteria [#/volume] in Urine by Automated count

280

2.86

2.64

5.4

4.5

—

121.20

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.96

2.63

1.7

1.5

—

(3021601) Nitrite [Presence] in Urine by Test strip

211

2.54

2.62

4.2

5.0

0.00

estimate

-0.00

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

7.74

2.60

1.0

1.9

—

(3034770) Mitochondria Ab [Titer] in Serum

7.74

2.60

1.0

1.1

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

2.79

2.54

1.7

—

(3029937) Albumin [Presence] in Urine by Test strip

118

2.50

2.52

4.1

0.00

estimate

-0.00

(3009261) Glucose [Presence] in Urine by Test strip

215

2.46

3.5

3.7

0.00

estimate

-0.00

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

6.77

2.42

1.8

1.9

227.40

204.75

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

6.77

2.42

1.6

1.0

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

6.77

2.42

1.0

1.8

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

5.06

2.34

1.2

—

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

6.00

2.26

2.0

1.8

77.80

95.11

—

(40768804) Tissue Pathology biopsy report

175

2.30

2.22

2.3

1.8

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

5.40

2.12

1.2

1.1

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

162

2.21

2.04

3.8

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

2.31

1.98

1.5

1.2

2.38

0.70

u/ml

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

3.35

1.87

1.7

1.3

—

(3041096) Erythrocytes [Presence] in Urine by Automated

124

2.16

1.84

3.6

3.3

—

(4200892) Spirometry reversibility

2.96

1.81

1.3

1.4

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

2.30

1.77

1.2

1.4

—

(3003327) Ova and parasites identified in Stool by Light microscopy

3.43

1.71

1.0

1.4

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

175

1.97

1.56

5.4

4.1

59.02

29.07

ng/l

0.53

125

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

3.09

1.55

18.8

5.0

23.90

25.39

mmol/l

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

2.12

1.55

1.8

1.3

12.55

40.51

iu/ml

—

(3014218) Bicarbonate [Moles/volume] standard in Arterial blood

2.94

1.48

19.3

6.5

24.80

24.40

mmol/l

—

(40758558) Short blood count panel - Blood

100

2.04

1.46

27.6

7.4

—

(40768797) Stomach Pathology biopsy report

2.18

1.44

1.5

1.2

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

171

1.89

1.39

2.7

1.9

85.14

97.07

pmol/l

0.74

(21494755) Public health laboratory ask at order entry panel

0.00

1.38

0.0

1.2

—

(4035726) Immunohistochemistry procedure

2.59

1.36

2.0

1.3

—

(3016502) Oxygen saturation in Arterial blood

2.29

1.32

15.3

5.4

95.09

95.92

—

(3003396) Base excess in Arterial blood by calculation

2.24

1.26

15.3

5.5

1.74

1.13

mmol/l

—

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

2.19

1.20

15.3

5.3

5.20

5.14

kpa

—

(3027801) Oxygen [Partial pressure] in Arterial blood

2.19

1.20

15.3

5.3

11.24

12.65

kpa

—

(3019060) Gas panel - Arterial blood

2.45

1.15

6.6

3.7

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

108

1.85

1.15

8.1

2.1

—

(3044640) Blood type and Crossmatch panel - Blood

146

1.74

1.05

8.2

2.2

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

1.93

1.03

2.6

3.2

3.29

4.03

e6/l

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

1.78

0.84

2.5

2.7

0.20

1.07

e6/l

—

(3002256) Pathology report gross observation

1.83

0.79

1.2

1.1

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

435

0.59

0.78

3.8

4.1

1.56

1.24

mmol/l

0.69

404

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.72

0.70

1.0

1.4

—

(3002173) Hemoglobin [Mass/volume] in Arterial blood

1.68

0.68

20.6

5.6

103.71

122.30

g/l

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

219

1.48

0.65

6.8

2.4

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.74

0.63

1.0

1.5

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

447

0.61

0.62

3.9

4.6

4.84

4.66

mmol/l

0.26

422

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.61

0.0

1.3

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.61

0.0

1.5

—

(3013512) EKG study

127

1.50

0.60

3.8

4.0

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.60

0.0

1.9

—

(3000991) Gas panel - Venous blood

1.70

0.58

19.0

4.8

—

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

156

1.46

0.57

8.4

2.9

28.30

29.08

u/l

0.10

143

(3012544) pH of Venous blood

1.65

0.56

2.5

2.6

—

(3019225) pH of Specimen

1.61

0.55

7.5

3.7

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

452

0.63

0.51

4.3

5.2

2.73

2.71

mmol/l

0.03

420

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

443

0.65

0.50

4.0

4.6

1.43

1.53

mmol/l

0.66

412

(3044889) 12 lead EKG panel

331

1.41

0.45

4.8

3.7

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

1.48

0.45

21.5

4.2

103.63

104.35

mmol/l

—

(36660697) Celiac disease serology panel - Serum

1.57

0.42

1.0

1.1

—

(3027008) Opiates [Presence] in Urine

0.00

0.42

0.0

1.3

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.52

0.41

1.2

1.6

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.47

0.40

1.6

1.5

—

(40761535) Cells panel - Urine sediment

1.35

0.24

3.2

3.3

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

3.1

—

18.64

—

(3014051) Protein [Presence] in Urine by Test strip

0.00

0.21

0.0

1.4

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

1.31

0.21

1.7

2.4

27.83

28.73

u/l

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.20

0.0

1.3

—

(1002224) Polysomnography panel

0.00

0.20

0.0

1.0

—

(4094501) Cardiovascular stress test using bicycle ergometer

0.00

0.20

0.0

1.0

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.17

0.16

1.4

1.3

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

434

1.27

0.16

4.1

4.8

5.92

mmol/l

0.00

402

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

125

1.16

0.11

4.1

3.4

1984.16

1239.80

ng/l

0.43

108

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.07

0.10

6.0

8.3

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.08

0.09

2.0

1.9

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

274

1.05

0.00

2.4

3.0

—

(3003694) ABO and Rh group [Type] in Blood

129

1.01

0.00

1.5

1.4

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.07

0.00

3.3

3.7

—

(3020682) Albumin/Creatinine [Ratio] in Urine

126

1.04

0.00

3.1

3.7

1.91

4.79

mg/mmol

—

(1761868) Lipid panel - Serum or Plasma

184

0.97

0.00

2.2

2.9

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

(40768806) Pleura Pathology biopsy report

0.00

0.0

2.9

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.0

1.3

—

(3012441) Differential panel - Pleural fluid

0.00

0.0

2.2

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

6.8

—

53.00

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.0

1.5

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.0

1.5

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.3

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.4

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

0.0

2.7

—

56.30

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3001788) Aldosterone [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

261.20

—

(3035880) pH of Pleural fluid

0.00

-0.00

0.0

1.2

—

(4146454) Self-monitoring of blood glucose

0.00

-0.00

0.0

3.4

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.8

—

1.64

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.8

—

4.82

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.6

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

-0.00

0.0

2.0

—

(3045788) Cell count panel - Pleural fluid

0.00

-0.00

0.0

1.6

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

0.00

-0.00

0.0

1.8

—

Mortality – FinRegistry

↥

Association

Association between endpoint L12_FEBRILENEUTROPHIL and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_FEBRILENEUTROPHIL.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: L12_FEBRILENEUTROPHIL – Febrile neutrophilic dermatosis [Sweet]

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Febrile neutrophilic dermatosis [Sweet]

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints